Metformin and Insulin: An Effective Therapeutic Combination for Overweight and Obese Type 1 Diabetes Patients?
Adrian Azka Ghafar1, Maftuchah Rochmanti2*, Hermina Novida3, Ahmad Ikhwanuddin Natsir4
Abstract
Type 1 Diabetes (T1D) is a chronic autoimmune disease characterized by insulin deficiency due to the destruction of pancreatic beta cells. Patients with T1D who are overweight or obese face additional challenges in management due to insulin resistance, making their condition more complex to treat. This systematic review evaluates the efficacy of adding metformin to insulin monotherapy in improving glycemic control and body mass index (BMI). This study retrieved data from databases including PubMed, ScienceDirect, Scopus, and ProQuest, adhering to PRISMA guidelines. After screening 402 studies, 4 randomized controlled trials met the inclusion criteria. These trials compared the impact of metformin with placebo or insulin monotherapy on HbA1c, fasting plasma glucose (FPG), and BMI. The results showed that metformin adjunct therapy provided limited impact on HbA1c and FPG levels while demonstrating significant improvements in BMI. In conclusion, adding metformin to insulin therapy can aid in improving BMI in overweight or obese T1D patients, though its effects on glycemic control remain inconclusive. Further high-quality studies are recommended to validate these findings.
Keywords
type 1 diabetes; obesity; overweight; insulin; metformin; glycemic; BMI.
Cite This Article
Ghafar, A. A., Rochmanti, M., Novida, H., Natsir, A. I. (2024). Metformin and Insulin: An Effective Therapeutic Combination for Overweight and Obese Type 1 Diabetes Patients?. International Journal of Scientific Advances (IJSCIA), Volume 5| Issue 6: Nov-Dec 2024, Pages 1495-1499, URL: https://www.ijscia.com/wp-content/uploads/2024/12/Volume5-Issue6-Nov-Dec-No.758-1495-1499.pdf
Volume 5 | Issue 6: Nov – Dec 2024
